HIGHLIGHTS
Drug-eluting stents impede neointimal smooth muscle cell hyperplasia but exacerbate endothelial cell dysfunction and thrombogenicity. It has been a challenge to identify a common target to inhibit both. Findings in this study suggest PERK as such a target.
A PERK inhibitor administered either via an endovascular (in biomimetic nanocarriers) or perivascular (in hydrogel) route effectively mitigated neointimal hyperplasia in rats.
Oral gavage of the PERK inhibitor partially preserved the normal blood flow in a mouse model of induced thrombosis.
Dampening PERK activity inhibited STAT3 while activating SRF in smooth muscle cells, and also reduced prothrombogenic tissue factor and growth impairment of endothelial cells.
SUMMARY
Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors' findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm. proliferative/migratory cells that form neointima (4, 5) . Thus, an ideal antirestenotic treatment should not only block SMC's phenotypic switching but also be EC-protective (6, 7) .
Drug-eluting stents (DES) are commonly deployed to reduce post-angioplasty restenosis. However, they do not completely prevent IH and, in fact, worsen thrombogenic risks (6) . In-stent restenosis occurs in w5% to 10% of coronary DES applications (8) and >50% peripheral DES applications (9) . Moreover, stent thrombosis has become a major concern, with up to 40% sudden death among those patients (10) .
Increasing evidence reveals that DES mitigate the disease phenotypes of SMCs but not that of ECs; rather, they elicit EC dysfunction (11, 12) . Dysfunctional ECs become growth-impaired and apoptotic, and produce thrombogenic factors (e.g., tissue factor) while releasing proinflammatory signal molecules that enhance SMC phenotypic switching thereby promoting IH and thrombosis (7, 13) . Therefore, the ultimate outcome of DES implantation for restenosis prevention, paradoxically, can be the persistence of in-stent restenosis and exacerbated thrombogenic risks in many patients (6) . Anticoagulant therapies cannot completely prevent stent thrombosis, and long-term application incurs a significant risk of hemorrhage (14) . To tackle the downsides of DES, alternative strategies such as drug-eluting balloons and biodegradable stents have been clinically tested. However, their applications still rely on EC-toxic drugs, and recent studies have demonstrated increased mortality associated with their usage (15) . Therefore, there is a clear clinical need for an endothelium-protective and stentfree antirestenotic therapy (16) . Currently, basic and translational research to address this need has been limited (11, 17) . In order to rescue the endothelium thereby reducing thrombogenic risk while mitigating IH, it is essential to identify and inactivate a common target in both SMCs and ECs that is responsible for their disease phenotypes.
Recently, endoplasmic reticulum (ER) stress response pathways have emerged as novel interventional targets for cardiovascular diseases. Three unique pathways, represented by inositol-requiring kinase 1 (IRE1), activating transcription factor 6 (ATF6), and protein kinase RNA-like endoplasmic reticulum kinase (PERK), are selectively or simultaneously activated depending on the ER stress context (18, 19) . Of note, the IRE1 and ATF6 pathways have been reported to play a significant role in restenosis and other vascular diseases (18, 19) . By contrast, the role of PERK in restenosis remained unclear. In this pathway, PERK serves as the sensor for ER stress; its autophosphorylated form activates elongation initiation factor (eIF)-2a. Activated eIF2a suppresses global protein translation while paradoxically activating the transcription of subsets of genes in a contextdependent fashion, for example, ATF4, a key counter-stress transcription factor (20) . In addition, activated PERK can also regulate other signaling pathways via its kinase activity (21) . Therefore, global translational repression, together with selective activation of a subset of genes as well as crosstalk with other pathways, all elicited by PERK activation, may define specific outcomes in a context (e.g., cell type) dependent manner (22) . Laboratories, Wilmington, Massachusetts) as previously described (16) . Briefly, rats were anesthetized with isoflurane (5% for inducing and 2.5% for maintaining anesthesia). A longitudinal incision was made in the neck, and the carotid arteries were exposed. A Drug delivery via biomimetic (platelet membrane-coated) nanoclusters that home to balloon-injured sites of rat carotid arteries was established in our recent report (16) . We used this targeted delivery method in the same rat angioplasty model for administration of vehicle to be nonimmunogenic and able to home to the injured artery wall following intravenous injection in the rat balloon angioplasty model (16) . To evaluate the effect of PERK inhibition on IH, we injected these A Potential Low-Thrombogenic Antirestenotic Paradigm Figure 1A) . At day 14, arteries were collected for histological analysis ( Figure 1B) . An inhibitory effect of GSK2606414 on PERK activation was confirmed by reduced phospho-PERK immunofluorescence (Supplemental Figure S1 ).
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Morphometric analysis showed a profound antirestenotic effect of GSK2606414 compared with vehicle control, with a >70% reduction in the intima to media (I/M) ratio and w30% increase in lumen area ( Figure 1C ). Of note, this 2.5 mg/kg dose is approximately one-fifth of that used in a perivascular hydrogel delivery route (see later in the text) ( Figure 2A) . Figure S2 ). eIF2a as a central effector kinase is one of the direct substrates of PERK (29) . Another central player in ER stress responses, ATF4, is a transcription factor downstream of eIF2a.
CHOP is a downstream transcription factor of the extended PERK pathway and is often associated with cell death when cellular stress is too severe (30) . It is noteworthy that the up-regulation of these players did not last throughout post-injury day 14 as P-PERK did. On the one hand, PERK has multiple alternative substrates such as NRF2 (31) . On the other hand, the P-eIF2a-ATF4-CHOP axis is also regulated by kinases other than PERK, for example, GCN2 and PKR (32) .
Therefore, we infer that given a 14-day time span, cross-talks of different pathways in the injured artery may have rendered the upregulation of the PERK downstream players temporally variable. Nonetheless, these results collectively indicate that the PERK pathway was strongly activated due to arterial injury, consistent with a role in neointima development and its targetability by an inhibitor as evidenced above (Figures 1 and 2) . Figure S3B) . Therefore, these gain-offunction results support a specific role for PERK in promoting neointima formation.
PERK ACTIVATION PROMOTES SMC PHENOTYPE
SWITCHING. Phenotypic switching of SMCs is the core cellular mechanism underlying the development of neointima lesion and consequential restenosis (5) . We therefore determined the specific function of PERK in this process via loss-and gain-of-function experiments. We used PDGF-BB, a widely used potent inducer, to stimulate SMC phenotypic switching which was measured as enhanced de-differentiation (decreased expression of SMC markers) and proliferation (BrdU incorporation and cyclin D1 expression).
As shown in Figure 4A , whereas treatment of human primary aortic SMCs with PDGF-BB stimulated PERK activation (Figures 4A, 4E, and 4I ) and cell A Potential Low-Thrombogenic Antirestenotic Paradigm proliferation ( Figure 4C, 4G, and 4K) , and reduced a-SMA by 2-to 3-fold ( Figures 4D, 4H, and 4L) , pretreatment with the PERK inhibitor GSK2606414
(1 mmol/l) abrogated these PDGF-induced changes ( Figures 4A to 4D) . We then confirmed this result via gene knockdown using a PERK-specific siRNA. The 5B ). Further, coimmunoprecipitation experiments showed that HA-STAT3 specifically pulled down endogenous PERK in a PDGF-dependent manner, and this STAT3/PERK association was blocked by pre-treatment with the PERK inhibitor ( Figure 5C ). Moreover, the PDGF-induced and PERK inhibitor-blocked coimmunoprecipitation was also observed between HA-STAT3 and MRTF-A, similar to the published evidence (36) . We were thus prompted to determine whether PERK regulates the SRF transcriptional activity. Indeed, PERK overexpression (vs. GFP control) markedly inhibited the SRF activity in SMCs transfected with a luciferase vector containing the SRFbinding motif (CArG box) ( Figure 5D ). ECs are extremely susceptible to inflammatory challenges; a cytokine storm following endovascular injury is known to be notoriously detrimental to the homeostasis of endothelium. We used TNF-a as a cytokine-storm mimic to induce EC dysfunction, as broadly performed in previous studies (37) . EC dysfunction manifests mainly as growth impairment, and elevated production and secretion of tissue factor, which is a potent proinflammatory factor and thrombosis initiator (11, 12) . As shown in Figure 6 , treatment of human primary aortic ECs with TNF-a activated PERK (Figures 6A and 6B ) and dramatically up-regulated tissue factor by 40-fold ( Figure 6C ) and hampered EC proliferation (BrdU assay) ( Figure 6D) ;
pre-treatment with the PERK inhibitor almost completely averted these changes. Importantly, TNFa-induced up-regulation of PERK and tissue factor, as well as its abrogation by PERK inhibitor, was replicated ex vivo using rat aortic artery explants ( Figure 6F) . At the transcription level, necrosis factorkappa B (NFkB) is known as a master transcription factor that dictates EC homeostasis or dysfunction if overactivated in a cytokine environment (38) .
Consistently, we observed TNF-a-stimulated p65 activation, which was attenuated by PERK inhibition ( Figure 6E) . Taken together, these results support a positive role for PERK in EC dysfunction in addition to that in SMC phenotypic switching. This finding is significant because PERK-mediated EC dysfunction (in particular tissue factor up-regulation) has not Figure S5 ).
DISCUSSION
The standard of care for occlusive cardiovascular diseases using DES is plagued by in-stent restenosis and thrombogenic risks (6, 11 (6, 11, 40) .
In the present study, PERK inhibition proved effective in containing IH/restenosis in 2 drastically different (peri-and endovascular) drug-delivery routes. Although the former was in line with a prospective antirestenotic method suited for open surgeries (e.g., coronary artery bypass grafting), the latter using a biomimetic nanoplatform was conceived for a stent-free paradigm to prevent postangioplasty restenosis, both of which we have described in our recent publications (16, 24) . Bypass surgery and angioplasty account for the majority of revascularization procedures. Of particular interest, endovascular administration of the PERK inhibitor GSK2606414 carried in lesion-homing biomimetic nanoclusters reduced IH by >70% with a drug dose w250to 800-fold lower than those used for direct intraperitoneal or systemic intravenous injection in different disease models (23, 27) . Consistently, in our recent study, endovascular delivery using this biomimetic nanoplatform reduced the antirestenotic effective dose of an epigenetic modulator (JQ1) by 70fold compared with delivery of naked drug (16) .
Whereas early studies using PERK inhibitors have noted systemic toxicity (23, 27) , this barrier in therapeutic translation may be resolved using our lesiontargeting endovascular delivery modality because it allows for the use of lower doses.
Lower effective dosages lend strong support to a target (PERK) specificity of the observed antirestenotic efficacy of GSK2606414. This is an important feature, especially in view of the use of pharmacological approaches to investigate the role for PERK in neointima formation. Arguing against possible off-target effects, the GSK2606414 dose in biomimetic nanoclusters is much lower than that in published studies that demonstrated a potent inhibition of PERK in several GSK2606414-treated tissues (23, 27) . These studies have confirmed that in a dose range of 50 to 150 mg/kg administered twice daily, GSK2606414 is an inhibitor highly selective for PERK over other ER stress response kinases. Chances of GSK2606414 off-target effects were also reduced in our second route of delivery, considering that the drug applied outside of the artery was not expected to enter circulation directly and rapidly (28 Figure S6 ).
Additional data in the current study indicated that the observed PERK function was probably mediated by NFkB (p65), the master transcription factor in ECs known to direct the expression of tissue factor (43). proliferation (17, 45) . However, these studies were conducted in global knockout animals, and hence their SMC-and EC-specific roles in vivo remained unclear. Moreover, currently, there are no potent and selective small molecule inhibitors available for these proteins, limiting their potential for interventional targeting. Of particular interest, it was recently discovered that PIK75, a preclinical selective inhibitor of PI3K/p110a, exhibited both antirestenotic and endothelium-protective effects in mouse models (11) .
The PIK75 effects were similar to that of overexpressing PI3K/p85a (11, 46) , which is the inhibitory A Potential Low-Thrombogenic Antirestenotic Paradigm pathway, was implicated in the development of restenosis, particularly in the acute phase (49) . Our data showed a relatively delayed peak of ATF4 expression post-angioplasty. This discrepancy is possibly relevant to a different experimental setting or signaling cascade. Interestingly, another major ER stress response pathway, IRE1/XBP1, was shown to be actively involved in SMC differentiation; its dysregulation led to SMC phenotypic switching and neointima formation (19) . Published evidence also implicates an involvement of ER stress response (or related) pathways in atherosclerosis and aneurysm (50, 51) . In aggregate, other reports and our current study underscore the importance of these pathways in SMC and EC pathophysiology and associated vascular diseases.
STUDY LIMITATIONS. Our study using rodent models revealed a potentially favorable role of PERK inhibition in stymying neointima and a potential antithrombogenic effect following vascular injury. This PERK-targeting paradigm implicates an improved strategy to deal with neointima and thrombogenicity, 2 issues persistent with DES. However, in the clinical setting, these 2 issues occur with the same injured artery where DES is implanted. Therefore, in future studies, the beneficial outcomes of PERK inhibition need to be further examined with models that better recapitulate human arterial pathophysiology (e.g.,
hypercholesterolemic rabbit aortic stenting model).
Along this line, insufficient re-endothelialization after DES implantation has been noted to heighten thrombogenic risks and also exacerbate restenosis (6) .
Although we observed that PERK inhibition rescued EC dysfunction in vitro, a potentially beneficial effect on re-endothelialization remains to be determined by optimizing conditions such as drug dosage, delivery frequency, and homing efficiency of the biomimetic drug carrier (Figure 1) . A Potential Low-Thrombogenic Antirestenotic Paradigm
